Changes in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer

ObjectiveTo assess the optimal timing and predictive value of early intra-treatment changes in multimodality functional and molecular imaging (FMI) parameters as biomarkers for clinical remission in patients receiving chemoradiation for head and neck squamous cell carcinoma (HNSCC).MethodsThirty-five patients with stage III-IVb (AJCC 7th edition) HNSCC prospectively underwent 18F–FDG-PET/CT, and diffusion-weighted (DW), dynamic contrast-enhanced (DCE) and susceptibility-weighted MRI at baseline, week 1 and week 2 of chemoradiation. Patients with evidence of persistent or recurrent disease during follow-up were classed as non-responders. Changes in FMI parameters at week 1 and week 2 were compared between responders and non-responders with the Mann–Whitney U test. The significance threshold was set at a p value of <0.05.ResultsThere were 27 responders and 8 non-responders. Responders showed a greater reduction in PET-derived tumor total lesion glycolysis (TLG40%; p = 0.007) and maximum standardized uptake value (SUVmax; p = 0.034) after week 1 than non-responders but these differences were absent by week 2. In contrast, it was not until week 2 that MRI-derived parameters were able to discriminate between the two groups: larger fractional increases in primary tumor apparent diffusion coefficient (ADC; p < 0.001), volume transfer constant (Ktrans; p = 0.012) and interstitial space volume fraction (Ve; p = 0.047) were observed in responders versus non-responders. ADC was the most powerful predictor (∆ >17%, AUC 0.937).ConclusionEarly intra-treatment changes in FDG-PET, DW and DCE MRI-derived parameters are predictive of ultimate response to chemoradiation in HNSCC. However, the optimal timing for assessment with FDG-PET parameters (week 1) differed from MRI parameters (week 2). This highlighted the importance of scanning time points for the design of FMI risk-stratified interventional studies.

[1]  J. Parsons,et al.  Misregulation of DNA damage repair pathways in HPV-positive head and neck squamous cell carcinoma contributes to cellular radiosensitivity , 2017, Oncotarget.

[2]  L. Holloway,et al.  Assessment of serial multi-parametric functional MRI (diffusion-weighted imaging and R2*) with (18)F-FDG-PET in patients with head and neck cancer treated with radiation therapy. , 2016, The British journal of radiology.

[3]  Ann D. King,et al.  Squamous cell carcinoma of the head and neck: diffusion-weighted MR imaging for prediction and monitoring of treatment response , 2010, European Radiology.

[4]  A. Heerschap,et al.  Assessment of absolute blood volume in carcinoma by USPIO contrast-enhanced MRI. , 2006, Magnetic resonance imaging.

[5]  F. Howe,et al.  Tumor R2* is a prognostic indicator of acute radiotherapeutic response in rodent tumors , 2004, Journal of magnetic resonance imaging : JMRI.

[6]  Su Jin Lee,et al.  The Correlations Between MRI Perfusion, Diffusion Parameters, and 18F-FDG PET Metabolic Parameters in Primary Head-and-Neck Cancer , 2015, Medicine.

[7]  Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol , 2017, Radiation oncology.

[8]  W. Oyen,et al.  18F-FLT PET/CT for Early Response Monitoring and Dose Escalation in Oropharyngeal Tumors , 2010, Journal of Nuclear Medicine.

[9]  G. Weinstein,et al.  Diffusion-Weighted Magnetic Resonance Imaging for Predicting and Detecting Early Response to Chemoradiation Therapy of Squamous Cell Carcinomas of the Head and Neck , 2009, Clinical Cancer Research.

[10]  Bernard Gallez,et al.  How does blood oxygen level‐dependent (BOLD) contrast correlate with oxygen partial pressure (pO2) inside tumors? , 2002, Magnetic resonance in medicine.

[11]  Tejinder Kataria,et al.  Clinical outcomes of adaptive radiotherapy in head and neck cancers. , 2016, The British journal of radiology.

[12]  B R Rosen,et al.  NMR imaging of changes in vascular morphology due to tumor angiogenesis , 1998, Magnetic resonance in medicine.

[13]  J. Overgaard,et al.  Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study , 2015, Acta oncologica.

[14]  John L. Humm,et al.  Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[15]  C. Zhou,et al.  Value of R2* obtained from T2*‐weighted imaging in predicting the prognosis of advanced cervical squamous carcinoma treated with concurrent chemoradiotherapy , 2015, Journal of magnetic resonance imaging : JMRI.

[16]  Sandra Nuyts,et al.  Diffusion-weighted magnetic resonance imaging early after chemoradiotherapy to monitor treatment response in head-and-neck squamous cell carcinoma. , 2012, International journal of radiation oncology, biology, physics.

[17]  A. Baer,et al.  Feasibility Analysis of the Parametric Response Map as an Early Predictor of Treatment Efficacy in Head and Neck Cancer , 2015, American Journal of Neuroradiology.

[18]  Lihong Qi,et al.  Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. , 2017, The Lancet. Oncology.

[19]  Steven Sourbron,et al.  Alterations in anatomic and functional imaging parameters with repeated FDG PET-CT and MRI during radiotherapy for head and neck cancer: a pilot study , 2015, BMC Cancer.

[20]  H. Tonami,et al.  Fractional Change in Apparent Diffusion Coefficient as an Imaging Biomarker for Predicting Treatment Response in Head and Neck Cancer Treated with Chemoradiotherapy , 2014, American Journal of Neuroradiology.

[21]  John Suckling,et al.  Informatics in Radiology (infoRAD): Magnetic Resonance Imaging Workbench: analysis and visualization of dynamic contrast-enhanced MR imaging data. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.

[22]  Eric J. W. Visser,et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  G. Yoo,et al.  PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report , 2016, Journal of Immunotherapy for Cancer.

[24]  David Atkinson,et al.  Computationally efficient vascular input function models for quantitative kinetic modelling using DCE-MRI , 2008, Physics in medicine and biology.

[25]  Avraham Eisbruch,et al.  Early prediction of outcome in advanced head-and-neck cancer based on tumor blood volume alterations during therapy: a prospective study. , 2008, International journal of radiation oncology, biology, physics.

[26]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[27]  S. Bhide,et al.  Repeatability and sensitivity of T2* measurements in patients with head and neck squamous cell carcinoma at 3T , 2016, Journal of magnetic resonance imaging : JMRI.

[28]  W. Oyen,et al.  The Predictive Value of Early Assessment After 1 Cycle of Induction Chemotherapy with 18F-FDG PET/CT and Diffusion-Weighted MRI for Response to Radical Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma , 2016, The Journal of Nuclear Medicine.

[29]  M. Borri,et al.  Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient-based treatment regimens for advanced head and neck cancer. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.